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Abstract
Glucosylceramide synthase (GCS) catalyzes the ﬁrst committed step in the biosynthesis of glucosyl-
ceramide (GlcCer)-related glycosphingolipids (GSLs). Although inhibitors of GCS, PPMP and PDMP
have beenwidely used to elucidate their biological function and relevance, our comprehensive litera-
ture review revealed that the available data are ambiguous.We therefore investigatedwhether and to
what extent GCS inhibitors affect the expression of lactosylceramide (LacCer), neolacto (nLc4 and
P1), ganglio (GM1 and GD3) and globo (Gb3 and SSEA3) series GSLs in a panel of human cancer
cell lines using ﬂow cytometry, a commonly applied method investigating cell-surface GSLs after
GCS inhibition. Their cell-surface GSL expression considerably varied among cell lines andmore im-
portantly, sublethal concentrations (IC10) of both inhibitors preferentially and signiﬁcantly reduced
the expression of Gb3 in the cancer cell lines IGROV1, BG1, HT29 and T47D, whereas SSEA3 was
only reduced in BG1. Unexpectedly, the neolacto and ganglio series was not affected. LacCer, the
precursor of all GlcCer-related GSL, was signiﬁcantly reduced only in BG1 cells treated with PPMP.
Future research questions addressing particular GSLs require careful consideration; our results indi-
cate that the extent to which there is a decrease in the expression of one or more particular GSLs is
dependent on the cell line under investigation, the type of GCS inhibitor and exposure duration.
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Introduction
The altered glycan moiety on glycosphingolipids (GSLs) has been con-
nected to malignant transformation (Hakomori 2002). GSLs are made
of a hydrophobic ceramide (Cer) lipid tail to which an oligosaccharide
head group such as glucose (Glc) or galactose (Gal) is attached to form
either glucosylceramide (GlcCer) or GalCer. GSLs are constituents of
each eukaryotic cell located at the outer layer of the plasma membrane
and play fundamental roles in cell adhesion, cell proliferation and dif-
ferentiation, protein and lipid trafﬁcking, signaling events, and even
function as binding ligands of bacterial toxins and viruses (Hakomori
1992; D’Angelo et al. 2013; Ishibashi et al. 2013; Jennemann and
Grone 2013).
GlcCer is the precursor to the synthesis of lactosylceramide
(LacCer) that is, in turn, the key precursor for further branching
into the neolacto, ganglio and globo series (Figure 1A). The transfer
of Glc to Cer is catalyzed by the glucosylceramide synthase [UDP-
glucose N-asylsphingosine glucosyl transferase (EC 2.4.1.80), GCS]
and is the ﬁrst committed and rate-limiting step in GSL biosynthesis
(Kan and Kolesnick 1992). GlcCer and GCS are therefore crucial
players in many biological processes and competitive GCS inhibitors
have been used to study the biological functions of GSLs in more detail
(Park et al. 2012).
We have previously shown that blood plasma-derived anti-glycan
antibodies discriminate ovarian cancer patients from healthy controls
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using glycan-based immunoassays (Pochechueva et al. 2011; Jacob
et al. 2012). More recently, the neolacto series GSL P1 (Figure 1A)
was identiﬁed on malignant tissue and cultured cancer cells and there-
fore may be considered as a cancer-associated carbohydrate (Jacob
et al. 2014). To investigate the still poorly understood cellular andmo-
lecular functions of neolacto series P1 and globo series P
k (Gb3), an-
other tumor-associated carbohydrate described in the literature
(Kovbasnjuk et al. 2005; Johansson et al. 2009) and encouraged by
previous studies showing that GCS inhibitors such as PPMP deplete
or reduce the expression of particular GSLs, we evaluated the possibil-
ity of depleting cancer cell lines from various cell-surface GSLs using
commercially available GCS inhibitors PPMP and PDMP. In order to
carefully design our study, we performed a systematic review of the
currently available literature in this context and investigated the effect
of both inhibitors on representative GSLs of the globo, neolacto and
ganglio series in various cell lines.
Results
Literature search
A total of 137 studies have been published since 1989. We identiﬁed
73 studies reporting on human cancer cell lines of different tissue that
were treated with either with PPMP or PDMP. Since 1989 a continu-
ously growing number of reports have been observed (Figure 1B). In
general, both GCS inhibitors were shown to cause cytotoxic, antipro-
liferative, antiangiogenic and tumor-volume-reducing effects, modu-
late drug responses in cell lines both cytodestructive (as a drug
sensitizer) and -protective (Morjani et al. 2001; Gouaze et al. 2005;
Ma et al. 2011; Basu et al. 2012), modulate the level of LacCer and
GlcCer and particular reduces the expression of Gb3 in cells (Johans-
son et al. 2009), modulated the transcription of a set of glycogenes
(Ma et al. 2009; Basu et al. 2012), affect protein and lipid trafﬁcking
and membrane metabolism (Stefanic et al. 2010) and affect signaling
Fig. 1. Glucosylceramide-related biosynthesis, the use of GCS inhibitors in the literature and the differential expression of GlcCer–GSL in a pool of cancer cell lines.
(A) Depiction of biosynthetic pathway of the globo, neolacto and ganglio series GSLs (respective shaded areas) from GlcCer and LacCer. The key step in this
biosynthesis of GlcCer-related GSLs is catalyzed by GCS and is competitively inhibited by PPMP and PDMP (red). GSLs of interest are highlighted in green. Gray
arrows indicate further extensions of GSLs. (B) Summarized literature showing cumulative increase of publications per year using either both or single inhibitor (top
left). Pie chart (top right) presenting the number of studies subdivide according to the origin of the cell lines investigated; >2 organs in one study (mixed) and ≤3
publications on one organ investigated summarized by “others”. Box plot (bottom left) showing the median and interquartile range of PPMP (green) and PDMP
(blue) concentrations used in the literature. Bar graph depicting the percentage of all studies for categorized time of treatments. (C) Flow cytometry data on nine
cancer cell lines shown as histogram for negative control (white area under the curve) and GSL-speciﬁcally stained sample (dark gray). The value provided in each
histogram refers to the percentage of positively stained cells and is a representative of three independent experiments.
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pathways in cells (Park et al. 2012). Most of the studies investigated
cancer cell lines originated from blood (27.5%; Figure 1B). PDMP
was generally used in higher concentrations than PPMP (Figure 1B).
Information on the mock control [dimethyl sulfoxide (DMSO), iso-
propanol or water] was provided in only one-fourth (24.7%) of the
studies and only 15.0% provided the information (IC10–50) on how
the concentration of the inhibitor(s) was determined. The duration
of the treatment varied from 30 min up to 168 h (Figure 1B). Particu-
larly interesting to us we found that less than half of the studies
(45.2%) addressed the issue of GCS inhibitor-mediated accumulation
of Cer or reduction of mainly gangliosides and globosides.
Expression of GSLs in different cancer cell lines
Before addressing the effect of PPMP and PDMP on GSL expression,
we measured the GSL content on the cell surface of nine cancer cell
lines (Figure 1C). The investigated glycan epitopes include GSLs
such as LacCer, globo (Gb3 and SSEA3), neolacto (nLc4 and P1)
and ganglio series (GM1 and GD3) (Figure 1C). We observed a dis-
tinct expression of cell-surface GSLs in tested cell lines (Figure 1C).
The precursor for all GlcCer-related GSL, LacCer, was highly ex-
pressed on BG1 (88%) and T47D (63%), moderately on IGROV1
and A2780 (12 to 30%) and absent on SKOV3, OVCAR5,
HCT116, HT29 and MCF7. All cell lines except for HT29 were posi-
tive for a globo series GSL, SSEA3. Another member of this series,
Gb3, was absent on A2780 and OVCAR5, weakly expressed on
SKOV3, HCT116 and MCF7 (2 to 20%) and highly expressed on
IGROV1, HT29 and T47D (41 to 67%) (Figure 1C). With regards
to neolacto series GSL, more than half of the cell lines were positive
for paragloboside (nLc4) except for HT29, T47D, MCF7 and
OVCAR5. The second GSL of this series, P1, was exclusively present
on IGROV1 conﬁrming our previous ﬁndings (Jacob et al. 2011,
2014). The ganglio series member GM1 was highly expressed in all
cell lines while GD3 was completely absent. In summary, all cancer
cell lines expressed at least two GSL on their cell surface but had sig-
niﬁcant differences in GSL distribution, ranging from 6 positive out of
7 measured GSL (IGROV1) to cancer cells expressing only 2 GSL
(OVCAR5 and HT29).
Effect of GCS inhibitors on the survival of cancer cell
lines and determination of optimal concentration and
incubation period
Based on the ﬂow cytometry data, we selected IGROV1, BG1, HT29
and T47D for further analysis according to the following criteria: (i) at
least one cell line from each cancer type, (ii) glycan expression,
(iii) moderate or high GSL expression and (iv) whether P1 and/or
Gb3 were expressed in cell lines as these are GSL of our primary inter-
est. HT29 was favored due to its higher expression of Gb3 than
HCT116. T47D and MCF7 were negative for the neolacto series
but T47D had generally higher expression of GSL compared with
MCF7 (Figure 1C).
In order to avoid the effects of PPMP and PDMP on the GSL ex-
pression, which are compromised by a reduction in cell survival, we
ﬁrst determined optimal inhibitor concentrations. MTT assay was
performed in order to obtain the inhibitory concentrations, i.e. the
“sublethal” concentrations for PPMP and PDMP (reduces cell
survival by no >10%, i.e. IC10) in combinations with different incu-
bation times (24–72 h). The IC10 was chosen since concentrations
were previously shown to be sufﬁcient to inhibit the GCS activity
leading to accumulation of ceramides in the cells (Baran et al.
2007). We also determined the IC50 concentrations in order to
compare the potency of both inhibitors to inﬂuence cell viability.
PPMP substantially decreased the cell viability (80–90%) and was
more cytotoxic in all cell lines than PDMP (50–85%). This observa-
tion was independent of the incubation time (Figure 2A). Both inhi-
bitors signiﬁcantly differed in their molarity based on IC10 and IC50
among three cell lines. The only exception was T47D, in which case
the treatment time over 24 and 72 h did not result in different cell
viabilities.
PPMP and PDMP selectively reduce GSLs in a cell
line-dependent manner
Both inhibitors were used to treat selected cell lines (IGROV1, BG1,
HT29 and T47D) using IC10 (Figure 2A) for 48 h following immuno
staining and ﬂow cytometry analysis on viable cells. We expected a re-
duction in all GlcCer-related GSLs on the cell surface. However, our
ﬁndings clearly demonstrates that Gb3 is the only GSL reduced on the
cell surface of almost all investigated cell lines (n = 4) and for both in-
hibitors. The only exception was observed in case of PDMP treatment
on T47D (Figure 2B). In contrast, the expression of the other globo
series GSL SSEA3 was only affected in BG1.
While PPMP signiﬁcantly reduced LacCer expression in BG1 cells,
PDMP did not affect LacCer expression in all cell lines. Unexpectedly,
remaining GSL levels (nLc4, GM1 and P1) were not changed by either
one or both GCS inhibitors.
Discussion
Chemical compounds PDMP and PPMP are structural analogs of cer-
amide and were designed to inhibit the GCS, the only known glycosyl-
transferase in the biosynthesis of GlcCer–GSLs. Consequently, an
inhibition of this enzyme is expected to result in reduction of
GlcCer–GSLs. We have demonstrated that the extent of the inhibitor-
induced decrease of GSL expression is different for each cell line. Some
GSLs are even not affected. Gb3 seems to be the only GSL which can
be generalized, exhibiting in signiﬁcant reduction in almost all cell
lines for both inhibitors (IC10). This is also in concordance with the
literature. However, we would expect a similar reduction for SSEA3,
a pentasaccharide GSL comprising of Gb3 in its carbohydrate moiety.
This was, however, not observed in our experiments, which may be
explained by SSEA3 being mentioned to be linked toN-glycopeptides
(Shevinsky et al. 1982). Another major ﬁnding is that we could not ob-
serve a marginal extent of reduction within the ganglio (GM1) and the
neolacto series (P1 and nLc4) GSLs. Therefore, our data suggest that
both inhibitors are not suitable to reduce GSL of these series in the
investigated cell lines.
The unexpected ﬁnding on selective reduction of GSLs using GCS
inhibitors could possibly be explained by the complex cellular turn-
over of GSLs. The GSL turnover is dependent on several factors
such as metabolic pathways and ﬂuxes, the ﬂow of the endo- and exo-
cytotic routes, the rate of plasma membrane turnover dependent on
functional status of a cell, and the occurrence of external stimuli
that may inﬂuence neosynthesis or degradation. Therefore, the half-
life of a certain GSL can vary from only a few hours to several days
(Tettamanti 2004). In the case of globosides, Gb3 may has a shorter
turnover compared with SSEA3 in our investigated cell lines and is
therefore affected by GCS inhibitors. This may also account for neo-
lacto and ganglio series. In addition, the latter may be mostly affected
by GCS inhibitors due to the fact that large amounts of gangliosides
are expressed in human tumors of the neuroectodermal origin and
only minor in normal tissue (Hakomori 1985).
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Another explanation for our observations may be found in the col-
lected data of our systematic review of the currently available literature
for the GCS inhibitor PPMP and PDMP affecting the expression of
members of the GlcCer-related GSL in human cancer cells. The litera-
ture search revealed that in most cases only one or two cell lines and
only a small set of GSL (mostly conﬁned to gangliosides) were inves-
tigated within a single study. None of the studies investigated three
GSL series in parallel. Moreover, the effect on the expression of
GlcCer, the direct product of GCS and LacCer, the branching point
for three major GlcCer-related GSL series was only determined in a
few cases. In contrast, our experimental setup studied the effect of
both inhibitors on a large panel of GSLs representing three GlcCer–
GSL series in four cell lines, all measured at the same time. Further dis-
crepancies among studies such as inhibitor concentrations, the treat-
ment duration and the type of the vehicle/mock (if provided) may
also cause variable results.
Chemical modiﬁcations at various sites of these inhibitors were de-
scribed in order to enhance their inhibitory effect and to increase the
extent of ceramide accumulation or of GlcCer-related GSL reduction.
A longer acyl chain in PDMP homologs consisting of various lengths
(C6–C18) more efﬁciently inhibited GlcCer synthesis in MDCK cells.
Chemical modiﬁcations at the fatty acid chain as well as replacement
of the morpholino with a pyrrolidoni ring forming D,L-threo-P4 en-
hanced the inhibitory activity (Abe et al. 1992). Phenyl group substi-
tutions resulting in the compound EtDO-P4 inhibited GCS at an IC50
of 90 nM (Lee et al. 1999) and therefore was more potent compared
with respective IC50 values in the current literature and to our data.
However, the same inhibitor displayed an IC50 at 4 µM in murine
myeloma cells (Manning and Radin 1999). Another important aspect
is off-target effects. Enantiomers of GCS inhibitors were shown
to raise ceramide levels by inhibition of a pathway forming
1-O-acylceramide that does not involve glucosylceramide synthesis
(Shayman et al. 2004). Other GCS inhibitors, Genz-123346
(Silberstein et al. 2011) and EXEL-0346 (Richards et al. 2012), have
been recently introduced and may enhance the impact on all GlcCer
GSLs.
The initial purpose of our study was to reduce Gb3 and P1 using
PPMPor PDMP in ovarian cancer cell lines. However, a reductionwas
only seen in case of Gb3 suggesting that both inhibitors can be applied.
In case of P1, we consider the tested GCS inhibitor strategy not suitable
to deplete cells of the neolacto series. We therefore conclude that a
careful consideration of the type of the inhibitor, of its appropriate
concentration, exposure duration and the type of cell line is recom-
mended for experimental studies in which the depletion of a particular
GSL is used to address the research question of interest. This, of
course, applies to all inhibitor-based studies.
Material and methods
A systematic literature search was performed for the identiﬁcation of
scientiﬁc papers addressing human cell lines in combination with
PPMP and PDMP using PubMed (http://www.ncbi.nlm.nih.gov/
pubmed). The following key words were used: “PPMP” and/or
“PDMP”, “PPMP and cancer” or “PDMP and cancer”. The retrieval
Fig. 2. Effect of PPMP and PDMP on cell survival and on expression of GSLs in IGROV1, BG1, HT29 and T47D cells. (A) MTT assay showing cell survival (ordinate) a
function of the indicated concentrations and treatment duration [24 h (red), 48 h (green) and 72 h (blue)] for PPMP (left panel) and PDMP (right panel). Results are
presented as percentage of the respective mock-treated control. Mean ± SD of three independent experiments performed in quadruplet cultures. The IC10 used for
further ﬂow cytometry experiments is shown for each cell line and inhibitor. (B) Box andWhisker plots representing inhibitor-induced (IC10) changes in expression of
individual GSLs (percentage of FITC-positive cells, ordinate) for each cell line (abscissa) after a 48 h treatment with DMSO (red), PPMP (green) or PDMP (blue). Data
are representative of four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 were obtained by two-way ANOVA.
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was limited from 1989 to August 2014 and included research papers
and scientiﬁc reports written in English.
Ovarian (IGROV1, A2780, SKOV3, BG1 and OVCAR5), colon
(HCT116 and HT29) and breast (T47D and MCF7) cancer cell
lines were grown in RPMI-1640 media (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS), penicillin (100 U/mL) and strep-
tomycin (100 µg/mL) (Sigma-Aldrich) at 37°C in a 95% humidiﬁed
atmosphere containing 5% CO2.
Primary antibodies to detect the cell-surface-associated GSL were
applied as follows: mouse IgM anti-LacCer (CD17) conjugated to bio-
tin (Ancell, USA, 1 : 200), rat IgM anti-Pk (Gb3) antibody (ABDsero-
tec, Germany, 1 : 200), rat IgM anti-SSEA3 antibody (eBioscience,
Austria, 1 : 200), mouse IgM anti-nLc4 (paragloboside) antibody
[clone 1B2 kindly provided by Prof. Mandel and Prof. Clausen
(Young et al. 1981), 1 : 10], human IgM anti-P1 antibody (Millipore,
Germany, 1 : 10), mouse IgG anti-GD3 (BD Pharmingen, Switzerland,
1 : 200) and Cholera toxin B subunit (1 mg/mL, Sigma, 1 : 200) to de-
tect GM1. Secondary antibodies (obtained from BD Pharmingen)
were used in 1 : 100 dilutions and include: mouse anti-rat IgM anti-
body conjugated to biotin, rat anti-mouse IgM conjugated to biotin,
mouse anti-human IgM conjugated to biotin and anti-mouse IgG/
IgM antibody conjugated to ﬂuorescein isothiocyanate. Cell-surface ex-
pressed GSL was detected with FITC streptavidin (1 : 200). Non-viable
cells were positively stained with 7-amino-actinomycin (BD Pharmin-
gen, 1 : 50). Isotype controls for each primary antibody were used
including puriﬁed rat IgM (BD Pharmingen), puriﬁed mouse IgM and
chrompure human IgM (JacksonImmunoResearch, USA).
D,L-Threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol
(PPMP; Sigma-Aldrich) and D,L-erythro-1-Phenyl-2-decanoylamino-
3-morpholino-1-propanol•HCl (PDMP; Matreya, USA) were ali-
quoted in DMSO to 20 and 50 mM stocks, respectively, and stored
at −20°C.
The MTT assay was performed to deﬁne the inhibitor concentra-
tion (IC50) and working concentration (IC10) for ﬂow cytometry ex-
periments. Cells seeded in 96-well plates (BD Falcon, Switzerland)
were incubated with various concentrations of PPMP, PDMP or re-
spective DMSO concentrations (mock control) for 24, 48 and 72 h.
Cell cultures were incubated withMTT-dye (Sigma) at ﬁnal concentra-
tion 500 µg/mL for 3 h. After removal of the supernatant 200 µL
DMSO was added to dissolve the crystals. The optical density (OD,
absorbance at 540 nm) was measured with a SynergyH1 Hybrid
Reader (Biotek, Switzerland). The data (mean ± SD of three independ-
ent experiments performed in quadruplets) were presented as the sur-
vival (percentage of control) calculated from the OD after subtraction
of the contribution of DMSOmock as a function of PPMP and PDMP
concentration and incubation time. IC10 and IC50 concentrations of
PPMP and PDMP were calculated by linear extrapolation.
To evaluate the distribution of GSL LacCer, Gb3, SSEA3, nLc4,
P1, GD3 and GM1, cells grown in T25 cm
2
ﬂask to 80% conﬂuence
were washed with PBS and harvested with 1× Cell Dissociation Solu-
tion non-enzymatic (Sigma-Aldrich) at 37°C. Cells were transferred to
a 96-well V-bottom micro test plate (105 cells/well), and pelletized at
400 × g for 5 min.
Primary antibodies were added to the cells, resuspended and incu-
bated on ice for 1 h. Cells were then washed twice with FACSWASH
(1%, w/v, BSA in PBS) and incubated with the respective secondary
antibodies. After additional washing, cells were incubated with strep-
tavidin conjugated to FITC on ice for 30 min. Removal of unbound
streptavidin was accomplished by additional washing. Following
ﬁnal washing, cells were re-suspended in 200 µL of FACSWASH and
immediately analyzed with the ﬂow cytometer (BD Accuri C6, BD
Pharmingen). Each cell line was gated individually to exclude debris
(FSC-A vs. SSC-A) and subjected to single cell gating FSC-A vs.
FSC-H. Doublets and non-viable cells were excluded from analysis
by gating width vs. 7-AAD. Data acquisition were performed using
(BD Accuri C6 software, BD Pharmingen), while data analysis were
performed using FlowJo v10.0.4 (Tree Star Inc., Ashland, USA).
All comparisons for the MTT assay were statistically evaluated
with two-tailed Student’s t-test. P-values of < 0.05 were considered
statistically signiﬁcant. Flow cytometry data were evaluated with
two-way ANOVA comparing mock control with GCS-inhibitor
treatments.
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